T1	Participants 60 91	patients receiving chemotherapy
T2	Participants 393 561	Patients with newly diagnosed small-cell lung cancer (SCLC) were treated with CAE chemotherapy (cyclophosphamide, doxorubicin, and etoposide) and placebo or filgrastim.
